Minimally Invasive Radioguided Parathyroidectomy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01530919

Acronym

MIRP

Enrollment

856

Registered

2012-02-10

Start date

1998-09-30

Completion date

2017-04-30

Last updated

2017-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hyperparathyroidism

Brief summary

The main purpose of this research study is to evaluate the effectiveness of a minimally invasive surgical approach to removing parathyroid gland(s). The researchers are also interested in analyzing abnormal parathyroid tissue for changes in genes and proteins that may contribute to overactive parathyroid gland(s).

Detailed description

The specific aims of this study are to determine the safety and efficacy of minimally invasive radioguided parathyroidectomy, to determine the positive and negative predictive value of sestamibi scanning to detect parathyroid adenomas, and to differentiate adenomas from parathyroid hyperplasia. In addition, this study aims to determine the value of intraoperative parathyroid hormone assay to verify biochemical cure of primary hyperparathyroidism, to determine whether minimally invasive radioguided parathyroidectomy is cos-effective, and to collect abnormal parathyroid tissue at the time of surgery for tissue analysis.

Interventions

PROCEDUREMinimally invasive radioguided parathyroidectomy

After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All patients with biochemical evidence of primary hyperparathyroidism

Design outcomes

Primary

Measure	Time frame
The positive and negative predictive value of sestamibi scanning to detect parathyroid adenomas.	2-3days

Secondary

Measure	Time frame
The value of intraoperative parathyroid hormone assay to verify biochemical cure or primary hyperparathyroidism	2-3 days
Collection of abnormal parathyroid tissue at the time of surgery for tissue analysis	day of surgery (1 day)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026